Diagnostic Accuracy of an Electronic Nose as Compared to Combined Conventional CT-Scanning, Autofluorescense Scopy for the Detection of Early Endobronchial Squamous Cell Cancer after prior History of Head-and-neck Cancer or Lung Cancer

Diagnostic Accuracy of an Electronic Nose as Compared to Combined Conventional CT-Scanning, Autofluorescense Scopy for the Detection of Early Endobronchial Squamous Cell Cancer after prior History of Head-and-neck Cancer or Lung Cancer - New Techniques ENT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36533

Enrollment

315

Registered

2011-03-21

Start date

2011-01-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Endobronchial Squamous Cell Cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Patients who received a curative treatment for head-and-neck or lung cancer, including all tumour stages. * Curative treatment > 1year ago * Smoker or ex-smoker * Age > 18 * Written informed consent.

Exclusion criteria

Exclusion criteria: * Residual cancer or recurrence at the time of screening with standard screening methods. * Contraindications to bronchoscopy, as noted in the Dutch consensus guideline *bronchoscopy* (2003) * Prior bronchoscopy with local treatment in the preceding two years. * Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections) or other conditions that, in the opinion of the investigator, would compromise study objectives. * Uncontrollable bleeding tendency.

Design outcomes

Primary

Measure	Time frame
Primary outcome: Identification of lung cancer, esophageal cancer or metastasis by molecular profiling in exhaled breath and endobronchial air as screening method in this high risk population.	—

Secondary

Measure	Time frame
Secondary outcome: Prevalence of early (microscopic) lung and esophageal cancer in curatively treated head and neck cancer/ lung cancer patients. Exploratory outcome: Site specific signal of pre-invasive lesions	—

Countries

Netherlands

Outcome results